The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Brain : a journal of neurology

• Publication date

  2016-09-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/brain/aww162PMID 27538418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications

  2017cited by this paper
• Emotional manifestations of PD: Neurobiological basis

  2016cited by this paper
• Interaction Between Brain Histamine and Serotonin, Norepinephrine, and Dopamine Systems: In Vivo Microdialysis and Electrophysiology Study

  2015cited by this paper
• Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment.

  2015cited by this paper
• Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.

  2015cited by this paper
• Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.

  2015cited by this paper
• Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms?

  2015cited by this paper
• New insight into the therapeutic role of the serotonergic system in Parkinson's disease.

  2015cited by this paper
• The serotonin transporter in psychiatric disorders: insights from PET imaging.

  2015cited by this paper
• Dorsal-to-Ventral Shift in Midbrain Dopaminergic Projections and Increased Thalamic/Raphe Serotonergic Function in Early Parkinson Disease

  2015cited by this paper
• Prediagnostic presentations of Parkinson's disease in primary care: a case-control study.

  2015cited by this paper
• Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

  2015cited by this paper
• Clinical spectrum of impulse control disorders in Parkinson's disease

  2015cited by this paper
• Course of psychiatric symptoms and global cognition in early Parkinson disease

  2014cited by this paper
• Apathy in untreated early‐stage Parkinson disease: Relationship with other non‐motor symptoms

  2014cited by this paper
• Evaluation des troubles comportementaux hyper- et hypodopaminergiques dans la maladie de Parkinson Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease

  2014cited by this paper
• Apathy, depression, and motor symptoms have distinct and separable resting activity patterns in idiopathic Parkinson disease

  2013cited by this paper
• A volumetric MRI study of limbic, associative and sensorimotor striatal subregions in schizophrenia.

  2013cited by this paper
• Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial

  2013cited by this paper
• Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.

  2013cited by this paper
• A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

  2012cited by this paper
• Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease

  2012cited by this paper
• Subcallosal cingulate deep brain stimulation for treatment-resistant unipolar and bipolar depression.

  2012cited by this paper
• Midbrain serotonin transporters in de novo and L‐DOPA‐treated patients with early Parkinson’s disease – a [123I]‐ADAM SPECT study

  2011cited by this paper
• Physical and clinical performance of the mCT time-of-flight PET/CT scanner

  2011cited by this paper
• Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study.

  2010cited by this paper
• Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction.

  2010cited by this paper
• Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.

  2010cited by this paper
• Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures

  2010cited by this paper
• Preserved serotonin transporter binding in de novo Parkinson’s disease: negative correlation with the dopamine transporter

  2010cited by this paper
• [Assessment of hyper- and hypodopaminergic behaviors in Parkinson's disease].

  2009cited by this paper
• Neuropsychiatric symptoms in Parkinson's disease

  2009cited by this paper
• Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.

  2009cited by this paper
• The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease

  2009cited by this paper
• Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment.

  2009cited by this paper
• Automatic segmentation of brain MRIs of 2-year-olds into 83 regions of interest

  2008cited by this paper
• Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C]DASB

  2008cited by this paper
• Spared Caudal Brainstem SERT Binding in Early Parkinson's Disease

  2008cited by this paper
• Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results

  2008cited by this paper
• Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.

  2007cited by this paper
• The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease

  2006cited by this paper
• Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.

  2005cited by this paper
• The Parkinson fatigue scale.

  2005cited by this paper
• Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system.

  2005cited by this paper
• Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region?

  2005cited by this paper
• Development and validation of the Neuropathic Pain Symptom Inventory

  2004cited by this paper
• Three‐dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe

  2003cited by this paper
• Positron emission tomography of striatal serotonin transporters in Parkinson disease.

  2003cited by this paper
• Tremor in Parkinson’s disease and serotonergic dysfunction

  2003cited by this paper
• The FAB: A frontal assessment battery at bedside

  2000cited by this paper
• Visualization of the dopamine transporter in the human brain postmortem with the new selective ligand [125I]PE2I.

  1999cited by this paper
• Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.

  1997cited by this paper
• Multimodal image coregistration and partitioning--a unified framework.

  1997cited by this paper
• Simplified reference tissue model for PET receptor studies.

  1996cited by this paper
• The Mattis Dementia Rating Scale

  1994cited by this paper
• Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

  1990cited by this paper
• An inventory for measuring clinical anxiety: psychometric properties.

  1988cited by this paper
• The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

  1988cited by this paper

• [Pathophysiological and neurobiological basis for the development of depression in patients with Parkinson's disease].

  2026cites this paper
• Depression and apathy in frontotemporal dementia: a short assessment of facts and outlook.

  2026cites this paper
• Maladie de Parkinson : physiopathologie, critères diagnostiques et signes cliniques

  2026cites this paper
• Predictive factors of global cognitive impairment in de novo Parkinson disease with normal cognition at baseline: a 10-year cohort study

  2026cites this paper
• Monoaminergic Networks of Cognitive and Behavioral Symptoms in Early Parkinson's Disease.

  2026cites this paper
• Bipolar Affective Disorder and Clinical Depression: Comparative Analysis of the Serotonergic System Role in Pathogenesis and Correction

  2025cites this paper
• Exploring behavioural symptoms and inhibitory control in Parkinson’s disease: Comparison between dementia and non-dementia cases

  2025cites this paper
• Fatigue and neuropsychiatric symptoms in Parkinson’s disease: a narrative review

  2025cites this paper
• Research progress of chronic fatigue in neurodegenerative diseases

  2025cites this paper
• Brain network connectivity underlying neuropsychiatric symptoms in prodromal Lewy body dementia.

  2025influential citation
• Neuroimaging Advances in Neuropsychiatric Symptoms Associated with Parkinson’s Disease

  2025cites this paper
• Pain and fatigue in Parkinson’s disease: advances in diagnosis and management

  2025cites this paper
• Multidimensional mechanisms of anxiety and depression in Parkinson's Disease: integrating neuroimaging, neurocircuits, and molecular pathways.

  2025cites this paper
• Early synaptic changes and reduced brain connectivity in PD-like mice with depressive phenotype

  2025cites this paper
• Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial

  2025cites this paper
• Serotonergic dysfunction in patients with impulse control disorders in Parkinson’s disease

  2025cites this paper
• Executive dysfunction in Parkinson's disease: From neurochemistry to circuits, genetics and neuroimaging.

  2025cites this paper
• Effects of Aerobic Exercise on Depressive Symptoms in People with Parkinson’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2025cites this paper
• New Perspectives on Parkinson's Disease Subtyping: A Narrative Review.

  2025cites this paper
• Brain-clinical signatures of basal ganglia-related dysfunctional reorganisation in Parkinson's disease

  2025cites this paper
• Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective

  2025cites this paper
• Nature’s Remedies: Exploring the Potential of Propolis to Alleviate Non-Motor Manifestations of Parkinson’s Disease

  2025cites this paper
• Carriers of Parkinson’s disease-linked SNCA Rep1 variant have greater non-motor decline: a 4 year follow up study

  2025cites this paper
• Synaptic Changes in Mice Lacking Alpha- and Gamma-Synucleins

  2025cites this paper
• Impaired unfolded protein response, BDNF and synuclein markers in postmortem dorsolateral prefrontal cortex and caudate nucleus of patients with depression and Parkinson's disease.

  2025cites this paper
• Prevalence, contributing factors, and clinical impact of apathy in Parkinson's disease.

  2025cites this paper
• Detection of anxiety and depression-like behavior and intra-brain pathological markers in Parkinsonian cynomolgus monkeys.

  2025cites this paper
• Apathy linked to higher amyloid burden and cognitive deterioration in Parkinson's disease

  2025cites this paper
• Understanding disrupted motivation in Parkinson's disease through a value-based decision-making lens.

  2025cites this paper
• A molecular convergence in the triad of parkinson’s disease, depressive disorder and gut health is revealed by the inflammation-miRNA axis

  2025cites this paper
• Parkinson's Disease and Cancer: Mechanistic Insights and Therapeutic Opportunities From Cancer Neuroscience

  2025cites this paper
• Differential involvement of neurotransmitter pathways in AD, bvFTD and MCI: Whole-brain MRI analysis.

  2025cites this paper
• A Hispanic Female Presenting With the Cultural Syndrome “El Salto” as a Psychosomatic Symptom of Anxiety

  2025cites this paper
• Motivation in Parkinson's disease: apathetic before you know it.

  2024cites this paper
• Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases

  2024cites this paper
• Striatal Serotonin 4 Receptor is Increased in Experimental Parkinsonism and Dyskinesia

  2024cites this paper
• Cardiovascular dysautonomia and cognitive impairment in Parkinson's disease (Review)

  2024cites this paper
• Establishing connectivity through microdissections of midbrain stimulation-related neural circuits

  2024influential citation
• German Society of Neurology guidelines for the diagnosis and treatment of cognitive impairment and affective disorders in people with Parkinson’s disease: new spotlights on diagnostic procedures and non-pharmacological interventions

  2024cites this paper
• THE HABENULA IN PARKINSON'S DISEASE: ANATOMY, FUNCTION, AND IMPLICATIONS FOR MOOD DISORDERS - A NARRATIVE REVIEW.

  2024cites this paper
• Alpha Synuclein Toxicity and Non-Motor Parkinson’s

  2024cites this paper
• A general clinical overview of the non-motor symptoms in Parkinson's disease: Neuropsychiatric symptoms.

  2024cites this paper
• Investigating affective neuropsychiatric symptoms in rodent models of Parkinson's disease.

  2024cites this paper
• Role of the globus pallidus in motor and non-motor symptoms of Parkinson’s disease

  2024cites this paper
• The AAV-α-Synuclein Model of Parkinson’s Disease: An Update

  2024cites this paper
• Navigating Diagnostic Challenges: A Case Report on Early Parkinson's Disease Identification

  2024cites this paper
• From Synaptic Physiology to Synaptic Pathology: The Enigma of α-Synuclein

  2024cites this paper
• Exploring Parkinson’s Disease-Associated Depression: Role of Inflammation on the Noradrenergic and Serotonergic Pathways

  2024cites this paper
• Dopaminergic changes in the subgenual cingulate cortex in dementia with lewy bodies associates with presence of depression

  2024cites this paper
• Association between the functional connectivity of ventral tegmental area-prefrontal network and pure apathy in Parkinson’s disease: a cross-sectional study

  2024cites this paper
• Functional connectivity-based classification of rapid eye movement sleep behavior disorder.

  2024cites this paper
• Dysfunction of motor cortices in Parkinson’s disease

  2024cites this paper
• Drug delivery for neurodegenerative diseases is a problem, but lipid nanocarriers could provide the answer

  2024cites this paper
• Behavioral disorders in Parkinson disease: current view

  2024cites this paper
• Exploring habenular structural connectivity in Parkinson's disease: insights from 7 T MRI study

  2024cites this paper
• Stratifying Risk for Cognitive Decline in Older Adult Populations using the Geriatric Depression Scale.

  2024cites this paper
• Psychiatric and cognitive symptoms of Parkinson's disease: A life's tale.

  2024cites this paper
• New insights into the effects of serotonin on Parkinson's disease and depression through its role in the gastrointestinal tract.

  2024cites this paper
• Acupuncture for early Parkinson’s disease with mild to moderate depression: a randomized controlled trial protocol with functional MRI

  2024cites this paper
• Exploring depression in Parkinson’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management

  2023cites this paper
• Dimensions of apathy in Parkinson's disease

  2023cites this paper
• Anxiety in synucleinopathies: neuronal circuitry, underlying pathomechanisms and current therapeutic strategies

  2023cites this paper
• Association between apathy in patients with maintenance dialysis and hospitalization or mortality: a prospective cohort study

  2023cites this paper
• The Role of α-Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features

  2023influential citation
• The challenging quest of neuroimaging: From clinical to molecular-based subtyping of Parkinson disease and atypical parkinsonisms.

  2023cites this paper
• Structural and Molecular Imaging for Clinically Uncertain Parkinsonism

  2023cites this paper
• Neurobiology of Depression in Parkinson's disease: Insights into Epidemiology, Molecular Mechanisms and Treatment Strategies.

  2023cites this paper
• Role of serotonin in modulation of decision-making in Parkinson’s disease

  2023cites this paper
• Apathy in Parkinson’s Disease: Clinical Patterns and Neurobiological Basis

  2023cites this paper
• A nomogram based on iron metabolism can help identify apathy in patients with Parkinson’s disease

  2023cites this paper
• Validation of the Arabic version of Parkinson's Disease Sleep Scale-Revised Version (PDSS-2).

  2023cites this paper
• Noradrenergic alterations in Parkinson’s disease: a combined 11C-yohimbine PET/neuromelanin MRI study

  2023cites this paper
• Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease

  2023cites this paper
• Impulsive-compulsive behaviour in early Parkinson’s disease is determined by apathy and dopamine receptor D3 polymorphism

  2023cites this paper
• Motivational and cognitive predictors of apathy after subthalamic nucleus stimulation in Parkinson's disease.

  2023cites this paper
• Impaired value-based decision-making in Parkinson’s disease apathy

  2023cites this paper
• Copy Number Variations in Neuropsychiatric Disorders

  2023cites this paper
• Premature drug reduction after subthalamic nucleus deep brain stimulation leading to worse depression in patients with Parkinson's disease

  2023cites this paper
• Imbalanced motivated behaviors according to motor sign asymmetry in drug-naïve Parkinson’s disease

  2023cites this paper
• Associations of Sleep Disorders With Depressive Symptoms in Early and Prodromal Parkinson’s Disease

  2022cites this paper
• Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment

  2022cites this paper
• Hot and Cold Cognitive Disturbances in Parkinson Patients Treated with DBS-STN: A Combined PET and Neuropsychological Study

  2022cites this paper
• Future Directions in Molecular Imaging of Neurodegenerative Disorders.

  2022cites this paper
• Prevalence and clinical aspects of depression in Parkinson's disease: a systematic review and meta‑analysis of 129 studies.

  2022cites this paper
• Premotor, nonmotor and motor symptoms of Parkinson's Disease: A new clinical state of the art.

  2022cites this paper
• Serotonergic system in vivo with [11C]DASB PET scans in GTP-cyclohydrolase deficient dopa-responsive dystonia patients

  2022cites this paper
• Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson’s Disease

  2022cites this paper
• Altered functional connectivity of ventral striatum subregions in de-novo parkinson's disease with depression.

  2022cites this paper
• Cortical macro and microstructural correlates of cognitive and neuropsychiatric symptoms in Parkinson's disease.

  2022cites this paper
• Limbic Serotonergic Plasticity Contributes to the Compensation of Apathy in Early Parkinson's Disease

  2022influential citation
• Early Parkinson’s Disease Phenotypes Tailored by Personality, Behavior, and Motor Symptoms

  2022cites this paper
• Psychological outcomes of the COVID-19 pandemic in patients with Parkinson’s disease: A systematic review

  2022cites this paper
• Fatigue in de novo Parkinson’s Disease: Expanding the Neuropsychiatric Triad?

  2022cites this paper
• Cognition and serotonin in Parkinson's disease.

  2022cites this paper
• Erythrocytic α-Synuclein Species for Parkinson’s Disease Diagnosis and the Correlations With Clinical Characteristics

  2022cites this paper
• Semiology and determinants of apathy across neurodegenerative motor disorders: A comparison between amyotrophic lateral sclerosis, Parkinson’s and Huntington’s disease

  2022cites this paper
• Mapping neuromodulatory systems in Parkinson’s disease: lessons learned beyond dopamine

  2022cites this paper
• Imaging the Limbic System in Parkinson’s Disease—A Review of Limbic Pathology and Clinical Symptoms

  2022cites this paper
• Impaired interhemispheric synchrony in Parkinson's disease patients with apathy.

  2022cites this paper
• Cerebellar and cortico-striatal-midbrain contributions to reward-cognition processes and apathy within the psychosis continuum

  2022cites this paper